Regenerative medicine for the heart

Pursuing a potential cure for heart failure,
one stage at a time

Organamet Bio is advancing a sequential pipeline of bioengineered therapy candidates across the full spectrum of heart failure — led by Lami-Pro™, being developed as a potential first disease-modifying biologic for heart failure with preserved ejection fraction (HFpEF), a condition with no approved disease-modifying therapy today.

Explore the pipeline → Investor access
$40MM Post-Seed + Series A HQ at ARMI | BioFabUSA Zero approved HFpEF biologics
A focused strategy

From a market-ready pipeline to a moonshot

Our founding vision — a fully bioengineered, patient-specific heart — remains the endgame. But great science reaches patients only when it is sequenced wisely.

Organamet leads with the fastest, most capital-efficient product in our portfolio: Lami-Pro™, an injectable biologic for HFpEF. It reaches the clinic first, validates our intellectual-property platform, and generates the licensing revenue that funds and de-risks the larger prizes behind it — Ventri-Pro™ and Your-Heart™.

Why lead with Lami-Pro™? →
Sequential commercialization
Launch first. Validate. Fund what's next.
1
Lami-Pro™
HFpEF · injectable biologic · lead
2
Ventri-Pro™
HFrEF · bioengineered cardiac-derived patch
3
Your-Heart™
End-stage HF · patient-specific heart
The pipeline

Three products across the full heart-failure spectrum

One regenerative platform, anchored by the decellularization and bioengineering patents of Dr. Doris Taylor.

Lead
HFpEF

Lami-Pro™

An injectable, patent-pending biologic delivered into cardiac muscle — designed to restore native proteins, reduce inflammation and fibrosis, and improve relaxation. Designed as a one-time treatment intended to reverse underlying disease processes.

First-in-human targeted in ~3 years
Near-term
HFrEF

Ventri-Pro™

A bioengineered cardiac-derived patch designed to slow dilated (HFrEF) heart-failure progression — intended to stabilize the heart, promote vascularization, and support an environment for regeneration before irreversible damage.

Demonstrated activity in preclinical models
Moonshot
End-stage HF

Your-Heart™

A fully bioengineered, patient-specific heart built from a patient's own cells — designed to reduce or eliminate the need for immunosuppression and to address the donor-supply ceiling. Our long-term aspiration for end-stage heart failure.

The platform endgame

All Organamet Bio product candidates are investigational, have not been approved by FDA or any regulatory authority, and their safety and effectiveness have not been established.

The opportunity

The deadliest, costliest disease in the world

Heart failure is the leading cause of death globally — and its largest segment has no disease-modifying therapy at all.

64M
people live with heart failure today
Projected to reach 75M by 2030
~$48B
heart-failure therapeutics market by 2030
From ~$26B in 2024 · ~10.5% CAGR
0
FDA-approved disease-modifying biologics for HFpEF
Roughly half of all heart failure
Trusted partners

Built on a foundation of advanced manufacturing

ARMI | BioFabUSA Advanced Solutions Life Sciences DEKA Research BioAssemblyBot® University of Minnesota & Texas Heart Institute lineage